Finance

Lists
22UA:FRA
BioNTech SE - ADR
€79.40
-0.06%
(-0.050) 1D
Aug 11, 10:00:00 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 22UA...
Open
€80.10
High
€80.35
Low
€79.40
Mkt. cap
23.31B
Avg. vol.
496.00
Volume
119.00
52-wk high
€105.50
52-wk low
€68.00
No. of employees
8K
Open
€80.10
High
€80.35
Low
€79.40
Mkt. cap
23.31B
Avg. vol.
496.00
Volume
119.00
52-wk high
€105.50
52-wk low
€68.00
No. of employees
8K
News stories
From web sources and news partners
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases. The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes. In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR
CEO-
Employees7.81K
Founded2008
Headquarters-
SectorBiotechnology
Websitebiontech.de
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
1.52B
907.40M
118.10M
105.60M
Cost of goods sold
148.30M
302.80M
71.40M
97.00M
Cost of revenue
148.30M
302.80M
71.40M
97.00M
Research and development expenses
564.80M
505.40M
557.00M
477.10M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
148.50M
217.90M
150.80M
197.80M
Operating expense
1.40B
907.20M
727.70M
860.40M
Total operating expenses
1.55B
1.21B
799.10M
957.40M
Operating income
-33.00M
-302.60M
-681.00M
-851.80M
Other non operating income
96.80M
-173.80M
42.10M
23.80M
EBT including unusual items
24.70M
-227.40M
-568.10M
-858.70M
EBT excluding unusual items
40.70M
-206.50M
-567.80M
-777.70M
Income tax expense
53.40M
77.60M
-36.20M
-37.90M
Effective tax rate
216.19%
-34.12%
6.37%
4.41%
Other operating expenses
690.30M
183.90M
19.90M
185.50M
Net income
-28.70M
-305.00M
-531.90M
-820.80M
Net profit margin
-1.89%
-33.61%
-450.38%
-777.27%
Earnings per share
-0.12
-0.33
-1.95
-2.22
Interest and investment income
-
265.50M
61.70M
66.40M
Interest expense
-2.60M
-
-4.00M
-3.50M
Net interest expenses
-2.60M
265.50M
57.70M
62.90M
Depreciation and amortization charges
-
-
-
-
EBITDA
91.20M
-266.95M
-559.70M
-585.70M
Gain or loss from assets sale
-1.30M
-800.00K
-100.00K
-900.00K
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps